AMEX · OGEN
Healthcare · Biotechnology
$0.50
Up+$0.01 (+2.54%)
Updated Sep 17, 2026, 3:28 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OGEN closed at $0.50 after 20 trading sessions, down 5.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $0.50 | $0.5163 | $0.48 | $0.50 | 54.73K |
| Sep 15, 2026 | $0.487 | $0.4988 | $0.4756 | $0.4876 | 25.53K |
| Sep 14, 2026 | $0.484 | $0.499 | $0.4775 | $0.499 | 24.66K |
| Sep 11, 2026 | $0.503 | $0.5036 | $0.478 | $0.478 | 67.02K |
| Sep 10, 2026 | $0.5051 | $0.5053 | $0.5025 | $0.5033 | 9.24K |
| Sep 9, 2026 | $0.52 | $0.52 | $0.5052 | $0.515 | 5.35K |
| Sep 8, 2026 | $0.51 | $0.5223 | $0.51 | $0.5223 | 12.63K |
| Sep 4, 2026 | $0.4992 | $0.52 | $0.4992 | $0.51 | 8.73K |
| Sep 3, 2026 | $0.5061 | $0.5234 | $0.496 | $0.4985 | 22.89K |
| Sep 2, 2026 | $0.508 | $0.5329 | $0.4973 | $0.5061 | 25.81K |
| Sep 1, 2026 | $0.496 | $0.5189 | $0.4958 | $0.499 | 16.25K |
| Aug 31, 2026 | $0.515 | $0.5268 | $0.4901 | $0.5098 | 101.21K |
| Aug 28, 2026 | $0.5289 | $0.533 | $0.523 | $0.5242 | 74.77K |
| Aug 27, 2026 | $0.528 | $0.54 | $0.5124 | $0.532 | 29.84K |
| Aug 26, 2026 | $0.54 | $0.54 | $0.5202 | $0.53 | 7.24K |
| Aug 25, 2026 | $0.505 | $0.528 | $0.505 | $0.5201 | 12.97K |
| Aug 24, 2026 | $0.52 | $0.5298 | $0.511 | $0.5195 | 30.53K |
| Aug 21, 2026 | $0.5312 | $0.5449 | $0.52 | $0.525 | 56.51K |
| Aug 20, 2026 | $0.546 | $0.551 | $0.5302 | $0.54 | 16.3K |
| Aug 19, 2026 | $0.5499 | $0.555 | $0.5302 | $0.5302 | 11.08K |
The latest Smart Investors Daily articles mentioning OGEN.
OGEN research
Company profile and research snapshot.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 3, 2021 | Goldman Sachs | Neutral | — |
| Apr 16, 2020 | H.C. Wainwright | Neutral | — |
| Nov 15, 2019 | UBS | Neutral | — |
| Apr 26, 2019 | H.C. Wainwright | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical
Benzinga · Mar 12, 2026
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced it has completed the first site
Benzinga · Mar 11, 2026
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions
Benzinga · Mar 10, 2026
Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it has received final Human
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OGEN.
No results
No recent SID articles mention OGEN.
